| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2803135101011 | 313510101 | NEVIRAPINE/VOCATE TAB 200MG/TAB BTx60 | 52.88 | 55.47 | 70.55 |
| 05/2018 | 2803135101028 | 313510102 | NEVIRAPINE/VOCATE TAB 200MG/TAB BTx120 | 93.06 | 97.62 | 124.17 |
For use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.
Nevirapine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of nevirapine does not compete with template or nucleoside triphosphates.
Symptoms of overdose include edema, erythema nodosum, fatigue, fever, headache, insomnia, nausea, pulmonaryinfiltrates, rash, vertigo, vomiting, and weight decrease.
90% (absolute bioavailability 93 ± 9%)
45 hours
Thus cytochrome P450 metabolism, glucuronide conjugation, and urinary excretion of glucuronidated metabolites represent the primary route of nevirapine biotransformation and elimination in humans. Only a small fraction (<5%) of the radioactivity in urine (representing <3% of the total dose) was made up of parent compound; therefore, renal excretion plays a minor role in elimination of the parent compound.
* 1.21 ± 0.09 L/kg